Press release

SeqOne Genomics appoints Martin Dubuc, Senior Pharmaceutical and Digital Health Executive to its Board of Directors

by
Welcome Martin Dubuc to the SeqOne Genomics board

M. Dubuc will strengthen the Board’s capabilities in the fields of personalized medicine and companion diagnostics

Montpellier, France – Thursday, 26th of October, 2024 – SeqOne Genomics, a French company specialized in artificial intelligence-enhanced genomic analysis solutions, is pleased to announce the appointment of Martin Dubuc to its board of directors.

SeqOne Genomics is at the forefront of genomic data analysis in clinical applications, pioneering innovative software solutions that leverage artificial intelligence enabling more precise and personalized medicine.

Mr. Martin Dubuc, is a seasoned senior executive with Global experience who most recently headed up Biogen’s Global Digital Health division driving personalized and digital medicine. He brings over two decades of experience in the pharmaceutical industry at Pfizer, Merck&Co and Biogen across France, Europe and US combined with thought leadership expertise in digital health.

Sacha Loiseau, Ph.D., chairperson of SeqOne Genomics’ Board, stated: “I am thrilled to welcome Martin Dubuc to SeqOne’s Board. His deep insights into the pharmaceutical industry, combined with his knowledge of digital health technologies, will be
instrumental in taking SeqOne Genomics to the next level and providing the most advanced genomic analysis solutions for the pharmaceutical industry.”

“I was immediately seduced by the combination of people, hard science and technical
expertise underlying SeqOne’s genomic analysis platform, coupled with their focus on developing in-vitro diagnostics and companion diagnostics making personalized medicine a reality for patients and bringing innovative capabilities as a strategic
partner to LifeScience companies across the lifecycle.” commented Mr. Dubuc, “The exponential and converging progress of technologies underlying genomic testing opens a new era of opportunities. SeqOne is well positioned to make a meaningful
difference for patients partnering with LifeScience companies catalyzing precision medicine therapy development, genetic disease diagnosis, personalized medicine, and companion diagnostics”.

Dr. Nicolas Philippe, CEO and co-founder of SeqOne Genomics, concluded: “Martin Dubuc is a very strong addition to our Board of Directors. Martin’s shrewd business acumen and knowledge of the pharmaceutical industry have already proven to add significant value and will continue to help us as we strengthen our pharma offering and expand internationally.”

About SeqOne Genomics:
SeqOne Genomics offers high-performance genomic analysis solutions for healthcare
providers, treating patients suffering from cancer, rare and hereditary diseases as well
as pharmaceutical companies developing new therapies. The solution supports both
short read and long-read nanopore sequencing and leverages advanced machine
learning coupled with the company’s proprietary genomics platform to dramatically
reduce turnaround times and costs while delivering comprehensive and actionable
insights for personalized medicine. The company has won numerous awards including
the iLab award and the ARC cancer foundation’s Hélène Stark prize and has twice been
nominated for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital
Investissement, Merieux Equity Partners, Omnes and Software Club.

Web: https://seqone.com

Contact:
Jean-Marc HOLDER
media@seqone.com
+33 (0) 9 54 40 42 84

SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients

by
  • The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors.  
  • SeqOne’s test simplifies the deployment of this test while reducing the number of inconclusive results, even when biopsies have low tumoral content.  
  • Test accuracy was validated with the PAOLA-1 reference cohort and is presented at ESMO-GYNAE Barcelona on the 24th of February, 2023

Barcelona, Montpellier – February 22nd 2023:  SeqOne, the provider of new-generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD test that renders Homologous Recombination Deficiency (HRD) testing more accessible to Ovarian cancer patients. HRD status is key in the prescription of PARP inhibitor Olaparib, which improves survival of HRD-positive patients.

SeqOne’s approach simplifies the deployment of this test so that it can be performed by any well-equipped lab. To do this, SeqOne has based its test on a combination of two easily performed genomic analyses, a targeted gene panel and a low-pass whole genome, that together give excellent results when compared with reference tests.  The test has also been validated on multiple sequencers and reagents.  These results were clinically validated through a retrospective analysis of the PAOLA-1 cohort that was initially used to demonstrate the efficacy of Olaparib for HRD-positive patients. The cohort remains the gold standard for clinically validating all subsequent HRD tests. 

Another key focus was to ensure that actionable results could be obtained even with biopsies of low sample quality (low tumoral content),  as this has proved to be a major obstacle to delivering usable results in clinical routine environments.  SeqOne was able to deliver actionable HRD scores using samples of lower quality than most other tests; as little as 20% of cellularity and 50 nanograms of genetic material.  

“One of ARCAGY-GINECO ’s missions is to allow the validation of HRD testing through clinical evaluation on the PAOLA-1 cohort and to offer the medical professionals a reliable and objective assessment of test performance “. Said Pr. Pujade Lauraine, Medical Director of ARCAGY-GINECO. “SeqOne approached us early on in order to validate their test and have delivered a solution that is easy to implement and delivers great performance. I am glad that the clinical evaluation of their test is being presented today by my colleague Romain Boidot at ESMO GYNAE in Barcelona.”.

“Our objective was to deliver an easy-to-use test that would work even with samples of low tumoral content while affording medical professionals the assurance of test quality through a recognized certification process” said Nicolas Philippe, CEO of SeqOne.  “I am proud that we have delivered on this objective”.

“As a user of SeqOne’s solution,  we are pleased with the ease of use, accuracy and its tolerance to samples of low-tumoral content” said Marie-Pierre Wissler, a pathologist working at Cypath.  “It means we can return an HRD status more often than we could with previous vendors while at the same time reducing turnaround time.”

Clinical evaluation of SeqOne HRD is presented at ESMO GYNAE, in Barcelona on Feb 24th, 2023, by Romain Boidot, molecular biologist at the Centre Régional de Lutte contre le Cancer Georges François Leclerc (CGFL) Dijon

The SeqOne HRD score was validated using a retrospective analysis of 364 ovarian cancer patients from the PAOLA-1 phase 3 clinical trial. There is the same survival benefit for HRD+ patients when being treated with olaparib plus bevacizumab compared to bevacizumab alone, regardless of whether SeqOne HRD or Myriad myChoice® CDx test was used to form the HRD subgroup. In addition, SeqOne HRD has a smaller rate of inconclusive results compared to the inconclusive rate obtained with Myriad myChoice® CDx. Additional analyses to evaluate the HRD biomarker have been conducted: (i) a replication analysis on 48 individuals to test the reproducibility of the BRCA variant calling approach and (ii) a comparison of HRD testing using either NovaSeq and NextSeq sequencers to perform sWGS. Both analyses confirm the robustness of the SeqOne test.

– ENDS –

About SeqOne Genomics
SeqOne Genomics specializes in high-performance genomic analysis solutions for use in healthcare and life science –  hospitals, research institutions, and pharmaceutical companies -. SeqOne’s mission is to make genomic analysis more accessible and effective, in order to improve treatments for patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. 

SeqOne’s platform supports both short-read and long-read nanopore sequencing and leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine.  https://www.seqone.com/

SeqOne media contacts
– Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
– Jean-Marc Holder – jm.holder@seqone.com / +33 (6) 03 24 57 56

About Cypath
CYPATH is an independent medical practice bringing together 75 private doctors specialized in Pathological Anatomy and Cytology, associated in SELAS (private practice company by simplified action) grouped on thirteen sites located in Auvergne-Rhône-Alpes, Bourgogne-Franche-Comté and Grand-Est. The group collaborates with nearly 90 healthcare institutions and many private practices, general or specialized (Dermatology, Radiology, Gynecology, Midwives …). https://www.cypath.fr/


About ARCAGY
ARCAGY (Association de Recherche sur les CAncers dont GYnécologiques) is a French nonprofit organization that conducts clinical research on gynecologic cancers. The organization’s mission is to stimulate research on gynecologic cancers, as well as to provide support and information to patients and their families.

ARCAGY-GINECO” is a group of clinicians and medical sites in France focused on clinical research to fight gynecological cancers, including ovarian, endometrial, and cervical cancers. It is dedicated to promoting research, innovation, and clinical trials in the field of gynecological oncology, and to improving the care and treatment of patients with these types of cancers. For more information: https://www.arcagy.org/

SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times

by

Montpellier, February 9th, 2023:  SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS).  The program involved using Oxford Nanopore’s revolutionary technology to sequence patients at the bedside, dramatically reducing turnaround times to obtaining actionable insights.  Patients were sequenced using Oxford Nanopore’s adaptive sampling option that makes it possible to target the parts of the genome of interesr for thrombotic microangiopathies (TMAs) and modify the read-depth to explore in detail the regions that contain complex mutations that are hard to detect using standard methods.  This Oxford Nanopore-based analysis was compared with traditional short read sequencing approaches in order to establish a benchmark against current standards of care and hence quantify benefits of nanopore sequencing.  So far, the program, has analyzed 15 patients demonstrating the potential of the approach and highlighting the following benefits when compared with short-read sequencing;

  • Significantly faster turnaround times of under three days from sample collection to clinical report versus 3-4 week turnaround using outsourced short read sequencing
  • Reliable detection of complex variants such as those affecting alternative complement pathways that are often duplicated
  • Detection of certain types of variants, notably CFH:CFHR1 hybrid gene mutations that cannot be detected using traditional short-read technology
  • A clear indication of those patients who will respond to one of the drugs that have proven effective in treating this disease; vitamin B12 in Cobalamin III deficiency or Eculizumab in case of complement alternate pathway dysregulation associated aHUS. 

TMAs, such as aHUS, are rare diseases primarily affecting the kidney.  They are hard to diagnose using traditional methods as they present as a number of nonspecific symptoms, such as severe hypertension, acute kidney injury/failure in the context of mechanical anemia and thrombocytopenia. TMAs lesions can be associated with many diseases and some genetic disorders linked to aHUS. Molecular diagnoses, in particular in genes associated with alternative complement pathway regulation, make it possible to identify patients that suffer from this condition as well as informing on possible therapeutic options for TMA/aHUS.  

“It is clear that a cost effective, rapid technology that can sequence long fragments of DNA, such as those provided by Oxford Nanopore and a robust interpretation solution such as SeqOne are necessary to extract the full potential of third generation sequencing technology in nephrology and aHUS” said Pr. Laurent Mesnard, the PI heading the study. 

In order to support the program, SeqOne implemented an Oxford Nanopore compatible long-read support capable of managing adaptive sampling data.  SeqOne is a CE-IVD compliant platform that simplifies the analysis and interpretation of the data enabling the rapid interpretation of patient files which in turn maximizes efficiencies and enables management of higher caseloads.

“SeqOne is convinced both of the clinical potential of Oxford Nanopore’s technology as well as the benefits of bedside sequencing enabled by Oxford Nanopore’s hyper-cost-effective sequencing solutions” said Nicolas Philippe, CEO of SeqOne.  “We are investing heavily to provide the best interpretation solution for the data provided in support of this exciting initiative”. 

“We are delighted to be part of this research project and to see the potential of nanopore sequencing in nephrology and TMA/aHUS. The technology offers the chance to improve outcomes with significantly faster turnaround times and the ability to identify complex variants.” Commented Dr Emma Stanton, VP Clinical, Oxford Nanopore Technologies.

On the basis of this successful program, SeqOne and CNR-MAT now plan to extend its investigation of the use of nanopore sequencing technology to qualify further patients eligible to actionable (Vitamin B12, Eculizumab) therapy as well as to investigate the impact of other variant types in patient prognosis during TMA/aHUS. 

– Ends –

About SeqOne Genomics

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution supports both short read and long-read nanopore sequencing and leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club.

Web: https://seqone.com

SeqOne Contacts:

  • Annie-Florence Loyer – afloyer@newcap.fr / +33 6 88 20 3559
  • Jean-Marc Holder – jm.holder@seqone.com / + 33 6 03 24 5756

About the French Thrombotic Microangiopathies National reference centre (CNR-MAT)

The Thrombotic Microangiopathies National reference centre (CNR-MAT) is a research network focused on the study of thrombotic microangiopathies (MAT) and associated rare diseases. It was recognized 2006 as a national reference center for France under the stewardship of Paul Coppo (Hematology department, Saint-Antoine Hospital and Sorbonne-University) in Paris. The missions of the CNR-MAT are to promote clinical and basic research in the field of thrombotic microangiopathies through innovative medical approaches, as well as to inform practitioners, patients and all actors involved in the management of these diseases. The CNR-MAT coordinates the healthcare establishments treating patients suffering from these pathologies in France.

Web: https://www.cnr-mat.fr

CNR-MAT Contact:

  • Raida Bouzid Saadaoui – raida.bouzid-saadaoui@aphp.fr

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. https://www.nanopore.com

Oxford Nanopore Technologies contact: media@nanoporetech.com 

Forward-looking statements 
This announcement contains certain forward-looking statements. Phrases such as “potential”, “expect”, “intend”, “believe we can”, “working to”, “anticipate”, “when validated”, and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business, and by definition address matters that are, to different degrees, uncertain and may involve factors beyond our control.

Michael Blum joins SeqOne Genomics to head the company’s Research and Development

by

Renowned specialist in healthcare data science, he will focus on developing A.I. driven genomic analysis solutions to facilitate personalised medicine in oncology and rare diseases

Montpellier, October 20, 2022 – SeqOne Genomics, today announced that Michael Blum, Ph.D. is joining the company to lead its research and development department. He is tasked with driving SeqOne’s R&D strategy notably in the area of rare diseases and oncology through the use of machine learning and data science.

Michael started his career as a biostatistician and bioinformatician at the CNRS where he developed software solutions that enabled complex genomic data analysis for biologists and clinicians. He then set up the Grenoble Data Institute, a cross-disciplinary research group, to study how digital technology and data could be harnessed to benefit science and society. In 2019, he joined Owkin where, for the past three years, he has developed AI-based solutions to optimize clinical trials.

At SeqOne, Michael will lead scientific research and the development of new genomic analysis solutions to improve the clinical interpretation and diagnosis of cancer and hereditary diseases. Michael Blum has co-authored over 50 scientific publications, many of which are the fruit of international collaborations in the fields of population genomics and genomic medicine.

Michael holds an engineering degree from Grenoble INP, a PhD in applied mathematics, and completed a post-doctorate in bioinformatics at the University of Michigan.

“SeqOne has developed an impressive set of ground-breaking technologies built on hard science”, said Michael Blum. “We share the same vision that aims to advance personalised medicine by creating a tight interaction between technology and medicine. I am honoured to be part of SeqOne’s management team, leading research initiatives to develop ever more effective diagnostic solutions that will accelerate access to personalized medicine for all patients.”

“Our whole team is delighted that Michael is joining us”, commented Nicolas Philippe, CEO and co-founder of SeqOne Genomics. “His vast expertise in data science and biology represents an extraordinary asset for the development of our international program to develop clinical genomic analysis solutions. His commitment to advancing and spreading knowledge will help extend our leadership among the key players in personalized genomic medicine.”

About SeqOne Genomics: 

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club. More information at: https://seqone.com

SeqOne Genomics media relations:  

  • Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
  • Juliette Milleret – jmilleret@newcap.fr /+33 (6) 98 50 21 93

SeqOne Genomics announces Portuguese distribution partnership

by

SeqOne has appointed ILC Instrumentos de Laboratório to distribute its genomic analysis software platform in Portugal, and to accelerate the availability of its advanced genomic analysis solutions.

Montpellier, France – Lisboa, Portugal – September 30th 2022 – SeqOne Genomics, provider of next-generation genomic analysis solutions for personalized medicine is proud to announce a new strategic partnership with  ILC Instrumentos de Laboratório Científicos to facilitate access to its genomic analysis solutions in Portugal.  Through this partnership, ILC Instrumentos de Laboratório Científicos has been appointed as a value added distributor in Portugal.

Nicolas Philippe, CEO co-founder of SeqOne Genomics, said “We were impressed with the capabilities of ILC to provide the high levels of qualified support and customer service that we feel are essential to medical teams performing genomic analysis in clinical environments. Having a strong local partner in Portugal is key in our European expansion to make genomic testing available to all who need it.”

The new distribution partnership signals SeqOne’s intention to capitalize on the fast-growing personalized medicine market in Portugal. 

“As the Portuguese market embraces personalized medicine, the market for genomic analysis solutions is expanding rapidly. SeqOne’s high performance genomic analysis platform gives us the confidence that we can address the needs of the market and thus capitalize on this growth. We were impressed by SeqOne’s ability to support the full range of genomic analysis requirements, from simple analyses of small gene panels to the entire genome in both cancer and inherited diseases.  This means that we can offer a complete solution that addresses our customers’ needs.” said Cristina Iglésias da Costa CEO of ILC.

About SeqOne Genomics: 

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club. More information at: https://seqone.com

SeqOne Genomics media relations  

  • Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
  • Juliette Milleret – jmilleret@newcap.fr /+33 (6) 98 50 21 93

About ILC Instrumentos de Laboratório Científicos :

ILC has been in the Portuguese market since 1977 and has since been supporting the scientific community in the pursuit of knowledge and excellence. ILC has since partnered with some of the best companies in the world of Chemistry, Biology and Industry, in order to bring to Portugal the right technology and knowledge to allow its customers to reach their goals in the search of a better world.

We are hiring a VP of Platform Sales

by

VP of Platform Sales:

SeqOne is a well-funded company developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The company’s vision is to develop a genomic analysis software solutions that dramatically reduce the resources needed to provide accurate genomic analysis while accelerating turnaround time. Our aim is to make genetic testing easier and more accessible in order to accelerate the adoption of personalized medicine. SeqOne addresses the operational challenges  facing Diagnostic labs in delivering NGS analysis at scale by offering applications to analyze a single-patient or an entire family to diagnose hereditary family disorders or to recommend the best therapeutic options in cancer and  other somatic diseases 

Job Description

As the VP of  Platform Sales, you will define the international sales and marketing strategy to support the company’s ambitious international growth targets. You will recruit and manage a global sales and marketing team capable of executing your strategy. In close and direct collaboration with the exec team and the board, you will execute on the commercial and marketing plan and provide reporting on progress. 

Missions :

  • Build the optimum structure for our business with the best leadership in place 
  • Drive sales strategy 
  • Manage and grow existing customers by sustaining revenue growth both in existing franchises and from new application and channels 
  • Relay market requirements to product owner and provide feedback on product roadmap to ensure platform fit with local market requirements 
  • Participate in development of sales materials and trainings to ensure optimal effectiveness of sales team
  • Implement local marketing including events, seminars, and other local events, working closely with strategy, customer success and technical team
  • Manage sales process and provide regular reporting
  • Define and structure sales process implementing required tools, such as CRM, where necessary
  • Explore and evaluate potential of new markets 
  • Define international sales team structure and co-manage recruitments working with HR, operations and recruiters as deemed necessary
  • Define and participate in onboarding process for new salespeople.

Experience and skills: 

  • Minimum 8 – 10 years of sales experience across Europe with proven track record of achievement gained in the leading and working on/in similar markets IVD companies, preferably in Genomics
  • Must have demonstrated outstanding people leadership capabilities 
  • Strong vision for the future growth 
  • Excels in communication up, down and across the to peers in the organization 

Corporate culture:

We are a fast growing, international and start-up based in Montpellier in the south of France. You will be joining a highly collaborative and agile company with a demonstrated track record in delivering best-in-class medical solutions that enjoy significant market traction. We have a work-hard-play-hard approach to challenges in both business and technical arenas. The company recently closed a €20M funding round brining the total funding raised to €25M.

Stay in the loop

Get notified of SeqOne new annoucements.

SeqOne Platform is an in vitro diagnostic medical device, CE-IVD certified, designed to perform bioinformatics analysis of raw high-throughput sequencing data to help diagnosis. Manufacturer: SeqOne Genomics (France). Please read the instructions provided in the user manual carefully. Modified October 4th, 2023.